Gilead’s twice-yearly injection for HIV prevention cut infections by 96% in a late-stage trial, the company said Thursday, building the case for regulatory approval of the treatment.
Source link
Gilead’s twice-yearly injection for HIV prevention cut infections by 96% in a late-stage trial, the company said Thursday, building the case for regulatory approval of the treatment.
Source link
